1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.

NMTRQ
9 Meters Biopharma, Inc.US flagOther OTC
0.00
USD
- -
- -
145.00Market Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
130.28
426.91
312.69
147.28
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-129.94
-416.15
-330.66
-225.11
-19.52
-19.52
-16.23
-11.64
-3.03
-3.38
-3.52
Free Cash Flow per Basic Share
-146.47
-280.47
-65.44
-305.33
-8.64
-12.26
-10.79
-4.28
-2.63
-2.87
-2.83
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-229.88
-644.86
-978.82
-1,162.57
-32.54
-35.15
-42.34
-25
-13.89
-16.41
-17.2
Tangible Book Value per Share
-20.28
-187.73
-311.78
2.57
-20.48
-2.96
-5.77
6.09
3.42
0.19
-0.48
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
2
5
12
13
13
Sales/Revenue/Turnover
3
11
8
4
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-97.71
-58.86
-78.15
-146.2
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-11
-9
-6
-12
-24
-27
-61
-37
-44
-46
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-99.74
-97.48
-105.75
-152.84
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1
-5
-9
- -
-12
-4
-10
32
42
2
-6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-1
-5
-6
2
-12
-4
-10
32
42
2
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
3
20
5
LT Borrowings
16
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
14
Market Capitalization
28
8
9

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
18
33
9
Cash, Cash Equivalents & STI
16
13
7
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
31
16
Payables & Accruals
7
9
8
ST Debt
3
20
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-81.26%
-94.23%
Free Cash Flow
- -
59.55%
16.45%
Net Income, GAAP
- -
45.26%
19%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.51
-0.66
-1.06
- -
-3.03
2022
-0.88
-0.86
-0.72
- -
-3.38
2023
-1.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Peter H. R. Green
Full Time Employees
10
Sector
Healthcare
Industry
Biotechnology
Address
4509 Creedmoor Road Raleigh NC United States of America 27612
IPO Date
Jul 8, 2016
CIK
0001551986
Website
9meters.com
Similar Companies
Pathfinder Cell Therapy, Inc. (PFND)
Orphazyme A/S (ORPHA.CO)
Odonate Therapeutics, Inc. (ODTC)
TuHURA Biosciences, Inc. (HURA)
RVL Pharmaceuticals plc (RVLPQ)
Biotest AG (BTTAY)
Business
9 Meters Biopharma, Inc. (NMTRQ) is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare digestive diseases, gastrointestinal conditions with unmet needs, and related debilitating disorders. The company offers a pipeline of drug candidates including vurolenatide, a proprietary Phase 3 long-acting glucagon-like peptide-1 (GLP-1) agonist for short bowel syndrome; larazotide acetate, a tight junction regulator in Phase 3 for celiac disease and Phase 2 for multi-system inflammatory syndrome; NM-002 and NM-003 for undisclosed rare diseases; NM-102, a small molecule peptide; and NM-136, a humanized monoclonal antibody targeting glucose-dependent insulinotropic polypeptide for obesity-related disorders such as Prader-Willi Syndrome. It operates primarily in North America, with licensing agreements including Amunix for XTEN technology, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Founded in 2014 and headquartered in Raleigh, North Carolina, the company targets rare and orphan patient populations in gastroenterology, advancing clinical compounds through outsourced development and manufacturing. In a significant operational change, 9 Meters Biopharma filed a voluntary petition for liquidation under Chapter 7 bankruptcy on July 17, 2023, in the U.S. Bankruptcy Court for the Eastern District of North Carolina, leading to halted operations and delisting to pink sheets trading. Prior recent developments included the 2021 acquisition of global rights to NM-136 (formerly LOB-0136) from Lobesity LLC for an upfront payment and milestones, broadening its pipeline without impacting short bowel syndrome and celiac programs.